Lactobacillus Reuteri Feasibility Study on Probiotic Treatment and Perinatal Microbiome

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Pregnancy
Interventions
DRUG

Probiotic lozenges

The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

DRUG

Placebo lozenges

The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

DRUG

Probiotic capsules

The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

DRUG

Placebo capsules

The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

DRUG

Probiotic chewing gum

The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.

Trial Locations (1)

Unknown

Sahlgrenska University Hospital, Gothenburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioGaia AB

INDUSTRY

lead

Sahlgrenska University Hospital

OTHER

NCT02693028 - Lactobacillus Reuteri Feasibility Study on Probiotic Treatment and Perinatal Microbiome | Biotech Hunter | Biotech Hunter